23655-60-9

Upstream product

• 108-24-7 acetic anhydride 
• 4613-62-1 3-deoxy-1,2;5,6-di-O-isopropylidene-α-D-glucofuranoside 
• 2457-93-4 (3aR,5S,6aR)-2,2-dimethyl-5-[(2R)-oxiran-2-yl]-3a,5,6,6a-tetrahydrofuro[2,3-d] [1,3]dioxole 
• 58475-16-4 [(2R)-2-[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d] [1,3]dioxol-5-yl]-2-hydroxy-ethyl]4-methylbenzenesulfonate 
• 327594-26-3 (1S)-1-[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol 
• 24707-87-7 (S)-2-(benzyloxy)-1-((3aR,5S,6aR)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)ethan-1-ol 
• 78784-99-3 (R)-2-(benzyloxy)-1-((3aR,5S,6aR)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)ethan-1-ol 
• 4005-46-3 3-deoxy-1,2-O-isopropylidene-D-glucose 
• 64-19-7 acetic acid 
• 16667-96-2 1,2,5,6-di-O-isopropylidene-α-D-glucofuranose-3-O-(S-methylxanthate) 
• 582-52-5 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 

Relevant academic research and scientific papers

TLR7 AGONISTS

The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.

Structurally altered substrates for DNA topoisomerase I. Effects of inclusion of a single 3'-deoxynucleotide within the scissile strand

A partial DNA duplex containing a high efficiency topoisomerase I cleavage site was substituted singly at each of three sites with 3'- deoxyadenosine. Depending on the site of substitution, the facility of the topoisomerase I-mediated cleavage or ligation